Gilboa Therapeutics
Targeting Solid Tumors

Autologous T cell therapy, genetically modified to attack tumor cells

(e.g., chimeric antigen receptors, CARs) among the most powerful tool to date in the hands of clinicians for treating cancer. Despite initial success in hematological malignancies, conventional CAR-T has demonstrated limited efficacy towards solid tumors which remain inaccessible. Dangerous side effects further limit the utility of current technologies.

​​

Therefore, there is an urgent need to develop next-generation T cell therapy capable of eradicating solid tumors.

 

Gilboa Therapeutics’ breakthrough SolidT technology attacks these solid tumor cells with unprecedented safety and efficiency, bringing about complete remission in mouse models.

 

SolidT cell therapy is based on T cells that are genetically engineered to express a modified, high-affinity antibody receptor. This antibody receptor allows the engineered T cells to identify targets through an antibody intermediate. Tumor cells labeled by a tumor-specific antibody are then targeted for efficient killing by these T cells.

​

SolidT cells are designed to deliver a highly specific and potent attack that results in eradication of tumor cells, leaving healthy tissue unharmed.